This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Malaria Parasites Evade Artemisinin
Tech medical breakthrough

Malaria Parasites Evade Artemisinin

Analysis based on 7 articles · First reported Jun 17, 2026 · Last updated Jun 18, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The discovery by Rajiv Gandhi Centre for Biotechnology could lead to new approaches in malaria treatment, potentially impacting pharmaceutical companies involved in anti-malarial drug development and research. While Artemisinin's efficacy is questioned in certain contexts, the findings open avenues for combination therapies or new drug targets, which could create new market opportunities.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Scientists at the Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), led by Christeen Davis and senior author Rajesh Chandramohanadas, have identified a new mechanism by which malaria parasites survive treatment with Artemisinin, the most widely used anti-malarial drug. The study, published in The Journal of Infectious Diseases, reveals that immature red blood cells (reticulocytes) provide a protective environment, challenging the long-held belief that drug resistance is solely due to genetic changes in the parasite. This breakthrough, in collaboration with Indian Institutes of Science Education and Research, Cosmopolitan Hospital, and CSIR-National Chemical Laboratory, suggests future therapies could target host-parasite interactions, potentially improving treatment outcomes, especially for vulnerable populations.

Entities Involved
oth
Rajiv Gandhi Centre for Biotechnology
The Rajiv Gandhi Centre for Biotechnology led the research that identified a new mechanism for malaria parasite resistance to artemisinin, enhancing its reputation and potential for future research funding.
Importance 100.0 Sentiment 70.0
per
Rajesh Chandramohanadas
As the senior author and Principal Investigator at Rajiv Gandhi Centre for Biotechnology, Rajesh Chandramohanadas played a key role in the discovery, enhancing his scientific reputation.
Importance 90.0 Sentiment 70.0
oth
Artemisinin
The effectiveness of Artemisinin, a widely used anti-malarial drug, is challenged by the new findings, which could lead to adjustments in its application and potentially new drug development strategies.
Importance 80.0 Sentiment 20.0
per
Christeen Davis
Christeen Davis led the research team at Rajiv Gandhi Centre for Biotechnology that made the breakthrough discovery, significantly contributing to the understanding of malaria parasite resistance.
Importance 80.0 Sentiment 60.0
per
Beena Pillai
As the Director of India — Department of Biotechnology-Rajiv Gandhi Centre for Biotechnology, Beena Pillai highlighted the importance of the discovery for improving malaria treatment strategies.
Importance 70.0 Sentiment 60.0
govactor
India — Department of Biotechnology
The India — Department of Biotechnology oversees the Rajiv Gandhi Centre for Biotechnology, which conducted the study, thus indirectly benefiting from the research's success.
Importance 40.0 Sentiment 50.0
oth
The Journal of Infectious Diseases
The The Journal of Infectious Diseases published the breakthrough study as an Editor's Choice article, highlighting its role in disseminating significant scientific findings.
Importance 30.0 Sentiment 50.0
oth
Cosmopolitan Hospital
The Cosmopolitan Hospital collaborated on the study, contributing to the research and sharing in the recognition of the discovery.
Importance 30.0 Sentiment 50.0
oth
CSIR-National Chemical Laboratory
The CSIR-National Chemical Laboratory collaborated on the study, contributing to the research and sharing in the recognition of the discovery.
Importance 30.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.